EGFR signaling pathway and related-miRNAs in age-related diseases: The example of miR-221 and miR-222

Frontiers in Genetics

Volumn 3, Issue DEC, 2012, Pages

  Teixeira, Ana L ^a,b   Gomes, Mónica ^a,b,c   Medeiros, Rui ^a,b,c,d  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c LPCC   (Portugal)

^d UNIVERSIDADE FERNANDO PESSOA   (Portugal)

Author keywords

Age related diseases; Cancer; EGFR; miR 221 222; MiRNAs; Neurodegenerative diseases

Indexed keywords

EID: 84876072586     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2012.00286     Document Type: Short Survey

References (64)

1. Amit, I., Wides, R., and Yarden, Y. (2007). Evolvable signaling net- works of receptor tyrosine kinases: relevance of robustness to malig- nancy and to cancer therapy. Mol. Syst. Biol. 3, 151.
2. Attar, R. M., Takimoto, C. H., and Gottardis, M. M. (2009). Castration-resistant prostate can- cer: locking up the molecular escape routes. Clin. Cancer Res. 15, 3251-3255.
3. Avraham, R., Sas-Chen, A., Manor, O., Steinfeld, I., Shalgi, R., Tarcic, G., et al. (2010). EGF decreases the abundance of microRNAs that restrain oncogenic transcription factors. Sci. Signal. 3:ra43. doi: 10.1126/scisignal.2000876
4. Bartolome, F., De Las Cuevas, N., Munoz, U., Bermejo, F., and Martin-Requero, A. (2007). Impaired apoptosis in lymphoblasts from Alzheimer's disease patients: cross-talk of Ca2+/calmodulin and ERK1/2 signaling pathways. Cell. Mol. Life Sci. 64, 1437-1448.
5. Bos, M., Mendelsohn, J., Kim, Y. M.,Albanell,J.,Fry,D.W.,and Baselga, J. (1997). PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number- dependent manner. Clin. Cancer Res. 3, 2099-2106.
6. Calin, G. A., and Croce, C. M. (2006). MicroRNA signatures in human cancers. Nat. Rev. Cancer 6, 857-866.
7. Chung, C. H., Ely, K., McGavran, L., Varella-Garcia, M., Parker, J., Parker, N., et al. (2006). Increased epider- mal growth factor receptor gene copy number is associated with poor prognosis in head and neck squa- mous cell carcinomas. J. Clin. Oncol. 24, 4170-4176.
8. Coldren, C. D., Helfrich, B. A., Witta, S. E., Sugita, M., Lapadat, R., Zeng, C., et al. (2006). Baseline gene expres- sion predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. Mol. Cancer Res. 4, 521-528.
9. Cooper, T. A., Wan, L., and Dreyfuss, G. (2009). RNA and disease. Cell 136, 777-793.
10. Coppola, V., De Maria, R., and Bonci, D. (2010). MicroRNAs and prostate cancer. Endocr. Relat. Cancer 17, f1-f17.
11. Costa, B. M., Viana-Pereira, M., Fernandes, R., Costa, S., Linhares, P., Vaz, R., et al. (2011). Impact of EGFR genetic variants on glioma risk and patient outcome. Cancer Epidemiol. Biomarkers Prev. 20, 2610-2617.
12. Currais, A., Hortobagyi, T., and Soriano, S. (2009). The neuronal cell cycle as a mechanism of patho- genesis in Alzheimer's disease. Aging (Albany NY) 1, 363-371.
13. Dahan, L., Norguet, E., Etienne- Grimaldi, M. C., Formento, J. L., Gasmi, M., Nanni, I., et al. (2011). Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal can- cer. BMC Cancer 11:496. doi: 10.1186/1471-2407-11-496
14. De las Cuevas, N., Urcelay, E., Hermida, O. G., Saiz-Diaz, R. A., Bermejo, F., Ayuso, M. S., et al. (2003). Ca2+/calmodulin-dependent mod ulation of cell cycle elements pRb and p27kip1 involved in the enhanced proliferation of lymphoblasts from patients with Alzheimer dementia. Neurobiol. Dis. 13, 254-263.
15. De Muga, S., Hernandez, S., Agell, L., Salido, M., Juanpere, N., Lorenzo, M., et al. (2010). Molecular alter- ations of EGFR and PTEN in prostate cancer: association with high-grade and advanced-stage car- cinomas. Mod. Pathol. 23, 703-712.
16. De Strooper, B. (2007). Loss-of- function presenilin mutations in Alzheimer disease. Talking point on the role of presenilin mutations in Alzheimer disease. EMBO Rep. 8, 141-146.
17. Du, L., and Pertsemlidis, A. (2011). Cancer and neurodegenerative disorders: pathogenic convergence through microRNA regulation. J. Mol. Cell Biol. 3, 176-180.
18. Feng, W., and Feng, Y. (2011). MicroRNAs in neural cell develop- ment and brain diseases. Sci. China Life Sci. 54, 1103-1112.
19. Fry, D. W., Kraker, A. J., McMichael, A., Ambroso, L. A., Nelson, J. M., Leopold, W. R., et al. (1994). A specific inhibitor of the epider- mal growth factor receptor tyrosine kinase. Science 265, 1093-1095.
20. Ghelani, H. S., Rachchh, M. A., and Gokani, R. H. (2012). MicroRNAs as newer therapeutic targets: a big hope from a tiny player. J. Pharmacol. Pharmacother. 3, 10.
21. Hamada, N., Fujita, Y., Kojima, T., Kitamoto, A., Akao, Y., Nozawa, Y., et al. (2012). MicroRNA expres- sion profiling of NGF-treated PC12 cells revealed a critical role for miR-221 in neuronal differ- entiation. Neurochem. Int. 60, 743-750.
22. Harder, J. M., and Libby, R. T. (2011). BBC3 (PUMA) regulates develop- mental apoptosis but not axonal injury induced death in the retina. Mol. Neurodegener. 6, 50.
23. Hayashi, T., Koyama, N., Gresik, E. W., and Kashimata, M. (2009). Detection of EGF-dependent microRNAs of the fetal mouse submandibular gland at embryonic day 13. J. Med. Invest. 56(Suppl.), 250-252.
24. Hebert, S. S., Papadopoulou, A. S., Smith, P., Galas, M. C., Planel, E., Silahtaroglu, A. N., et al. (2010). Genetic ablation of Dicer in adult forebrain neurons results in abnor- mal tau hyperphosphorylation and neurodegeneration. Hum. Mol. Genet. 19, 3959-3969.
25. Heist, R. S., and Christiani, D. (2009). EGFR-targeted therapies in lung cancer: predictors of response and toxicity. Pharmacogenomics 10, 59-68.
26. Iorio,M.V.,Ferracin,M.,Liu,C.G., Veronese, A., Spizzo, R., Sabbioni, S., et al. (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65, 7065-7070.
27. Kim, E. M., and Hwang, O. (2011). Role of matrix metalloproteinase-3 in neurodegeneration. J. Neurochem. 116, 22-32.
28. Kim, J., Inoue, K., Ishii, J., Vanti, W. B., Voronov, S. V., Murchison, E., et al. (2007). A MicroRNA feedback circuit in midbrain dopamine neu- rons. Science 317, 1220-1224.
29. Kumar, M. S., Lu, J., Mercer, K. L.,Golub,T.R.,and Jacks,T. (2007). Impaired microRNA pro- cessing enhances cellular transfor- mation and tumorigenesis. Nat. Genet. 39, 673-677.
30. Kwak, E. L., Jankowski, J., Thayer, S. P., Lauwers, G. Y., Brannigan, B. W., Harris, P. L., et al. (2006). Epidermal growth factor recep- tor kinase domain mutations in esophageal and pancreatic adeno- carcinomas. Clin. Cancer Res. 12, 4283-4287.
31. Lee, J., Jang, K. T., Ki, C. S., Lim, T., Park, Y. S., Lim, H. Y., et al. (2007). Impact of epidermal growth fac- tor receptor (EGFR) kinase muta- tions, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer 109, 1561-1569.
32. Lee,J.W.,Soung,Y.H.,Kim,S.Y.,Nam, H. K., Park, W. S., Nam, S. W., et al. (2005). Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin. Cancer Res. 11, 2879-2882.
33. Li, T., Wen, H., Brayton, C., Das, P., Smithson, L. A., Fauq, A., et al. (2007). Epidermal growth factor receptor and notch pathways partic- ipate in the tumor suppressor func- tion of gamma-secretase. J. Biol. Chem. 282, 32264-32273.
34. Liu,W.,Innocenti,F.,Wu,M.H.,Desai, A. A., Dolan, M. E., Cook, E. H. Jr., et al. (2005). A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res. 65, 46-53.
35. Long, R. M., Morrissey, C., Fitzpatrick, J. M., and Watson, R. W. (2005). Prostate epithelial cell differenti- ation and its relevance to the understanding of prostate cancer therapies. Clin.Sci.(Lond.)108, 1-11.
36. Manolis, A. S., and Manolis, T. A. (2012). Micro RNAs: a revolution- ary discovery in biology. Hospital Chronicles 7, 5.
37. Medina, R., Zaidi, S. K., Liu, C. G., Stein, J. L., Van Wijnen, A. J., Croce, C. M., et al. (2008). MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. Cancer Res. 68, 2773-2780.
38. Miller, T. E., Ghoshal, K., Ramaswamy, B.,Roy,S.,Datta,J.,Shapiro, C. L., et al. (2008). MicroRNA- 221/222 confers tamoxifen resis- tance in breast cancer by target- ing p27Kip1. J. Biol. Chem. 283, 29897-29903.
39. Morris, L. G., Veeriah, S., and Chan, T. A. (2010). Genetic determinants at the interface of cancer and neurode- generative disease. Oncogene 29, 3453-3464.
40. Negrini, M., Nicoloso, M. S., and Calin, G. A. (2009). MicroRNAs and cancer-new paradigms in molecular oncology. Curr. Opin. Cell Biol. 21, 470-479.
41. Press, O. A., Zhang, W., Gordon, M. A., Yang, D., Lurje, G., Iqbal, S., et al. (2008). Gender-related survival dif- ferences associated with EGFR poly- morphisms in metastatic colon can- cer. Cancer Res. 68, 3037-3042.
42. Rao, X., Di Leva, G., Li, M., Fang, F., Devlin, C., Hartman-Frey, C., et al. (2011). MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene 30, 1082-1097.
43. Repetto, E., Yoon, I. S., Zheng, H., and Kang, D. E. (2007). Presenilin 1 regulates epidermal growth factor receptor turnover and signaling in the endosomal-lysosomal pathway. J. Biol. Chem. 282, 31504-31516.
44. Rosenberg, G. A., Cunningham, L. A., Wallace, J., Alexander, S., Estrada, E. Y., Grossetete, M., et al. (2001a). Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures. Brain Res. 893, 104-112.
45. Rosenberg, G. A., Sullivan, N., and Esiri, M. M. (2001b). White matter damage is associated with matrix metalloproteinases in vascular dementia. Stroke 32, 1162-1168.
46. Saito, Y., and Saito, H. (2012). MicroRNAs in cancers and neu- rodegenerative disorders. Front. gene. 3:194. doi: 10.3389/fgene. 2012.00194
47. Shah, M. Y., and Calin, G. A. (2011). MicroRNAs miR-221 and miR-222: a new level of regulation in aggres- sive breast cancer. Genome Med. 3, 56.
48. Shah, P. P., Hutchinson, L. E., and Kakar, S. S. (2009). Emerging role of microRNAs in diagnosis and treat- ment of various diseases including ovarian cancer. J. Ovarian Res. 2, 11.
49. Shalgi, R., Brosh, R., Oren, M., Pilpel, Y., and Rotter, V. (2009). Coupling transcriptional and post- transcriptional miRNA regulation in the control of cell fate. Aging (Albany NY) 1, 762-770.
50. Sharma, S. V., Bell, D. W., Settleman, J., and Haber, D. A. (2007). Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7, 169-181.
51. Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., et al. (1995). Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375, 754-760.
52. Shioya, M., Obayashi, S., Tabunoki, H., Arima, K., Saito, Y., Ishida, T., et al. (2010). Aberrant microRNA expres- sion in the brains of neurodegen- erative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3. Neuropathol. Appl. Neurobiol. 36, 320-330.
53. Sibilia, M., Kroismayr, R., Lichtenberger, B. M., Natarajan, A., Hecking, M., and Holcmann, M. (2007). The epidermal growth factor receptor: from development to tumorigenesis. Differentiation 75, 770-787.
54. Srivastava, S. K., Somvanshi, S., and Singh, V. P. (2012). Micrornas are not that small to ignore. Am. J. Biochem. Biotechnol. 8, 8.
55. Stinson, S., Lackner, M. R., Adai, A. T., Yu, N., Kim, H. J., O'Brien, C., et al. (2011). TRPS1 targeting by miR- 221/222 promotes the epithelial-to- mesenchymal transition in breast cancer. Sci. Signal. 4:ra41. doi: 10.1126/scisignal.2001538
56. Sun,T.,Wang,Q.,Balk,S.,Brown, M.,Lee,G.S.,and Kantoff,P. (2009). The role of microRNA-221 and microRNA-222 in androgen- independent prostate cancer cell lines. Cancer Res. 69, 3356-3363.
57. Teixeira,A.L.,Ribeiro,R.,Cardoso,D., Pinto, D., Lobo, F., Fraga, A., et al. (2008). Genetic polymorphism in EGF is associated with prostate can- cer aggressiveness and progression- free interval in androgen blockade- treated patients. Clin. Cancer Res. 14, 3367-3371.
58. Teixeira,A.L.,Ribeiro,R.,Morais, A., Lobo, F., Fraga, A., Pina, F., et al. (2009). Combined analysis of EGF+61G>A and TGFB1+869T>C functional polymorphisms in the time to androgen independence and prostate cancer susceptibility. Pharmacogenomics J. 9, 341-346.
59. Teixeira, A. L., Silva, J., Ferreira, M., Marques, I., Gomes, M., Maurício, J., et al. (2012). Circulating microRNA-222 in plasma - a potencial biomarker for renal cell carcinoma. Eur. J. Cancer 48(Suppl.), 5.
60. Teixeira,A.L.,Teixeira,A.L.,Araujo, A., Coelho, A., Ribeiro, R., Gomes, M., et al. (2011). Influence of TGFB1+869T>Cfunctionalpoly- morphism in non-small cell lung cancer (NSCLC) risk. J. Cancer Res. Clin. Oncol. 137, 435-439.
61. Vicentini, C., Festuccia, C., Gravina, G. L., Angelucci, A., Marronaro, A., and Bologna, M. (2003). Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures. J. Cancer Res. Clin. Oncol. 129, 165-174.
62. Wang,W.S.,Chen,P.M.,Chiou, T.J.,Liu,J.H.,Lin,J.K.,Lin, T. C., et al. (2007). Epidermal growth factor receptor R497K poly- morphism is a favorable prognos- tic factor for patients with colorec- tal carcinoma. Clin. Cancer Res. 13, 3597-3604.
63. Webster, R. J., Giles, K. M., Price, K. J., Zhang, P. M., Mattick, J. S., and Leedman, P. J. (2009). Regulation of epidermal growth factor recep- tor signaling in human cancer cells by microRNA-7. J. Biol. Chem. 284, 5731-5741.
64. Zhang,C.,Zhang,J.,Hao,J.,Shi,Z., Wang, Y., Han, L., et al. (2012). High level of miR-221/222 confers increased cell invasion and poor prognosis in glioma. J. Transl. Med. 10, 119.